Ready To Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
Or call (215) 966-6061
PSEUDOTYPED REPORTER VIRUS PARTICLES (RVPs)
Accelerating the discovery of vaccines and antiviral therapies against SARS-CoV-2, influenza, dengue, Zika, and other viruses
Reporter Virus Particles: Pseudoviruses for Safe Neutralization Data
Reporter Virus Particles (RVPs) are replication-incompetent pseudovirus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation.
- Safe in a BSL-2 environment
- Quantitative (luciferase) or fluorescent (GFP) read-out
- Quality-controlled critical reagents based on 20+ years of virology expertise and experience manufacturing reporter viruses
“SARS-CoV-2 RVPs really helped us a lot since we did not have much previous expertise in SARS. The user meetings were especially helpful.”
Accelerating Clinical Development: RVPs for Vaccines and Antibodies
The Integral Advantage: 20+Years of Virology Experience
Deep expertise in virology is at the core of Integral Molecular’s 20-year history, and we have co-authored over 70 peer-reviewed virology publications in journals including Cell, Science and Nature. With the support of NIAID, scientists at Integral Molecular have been on the forefront of combatting viral epidemics including COVID-19, Zika, Ebola, and Chikungunya. Meet our team.
Trusted by 100+ Laboratories for R&D and Clinical Trials
Publications Establishing RVPs as a Critical Reagent
Frequently Asked Questions
Are RVPs the same as live virus?
How are RVPs used?
What is the RVP readout?
What vaccine development services do you offer?
Do you offer custom RVPs?
Do you offer large lots or volumes of RVPs?
